Thank you, Mr. Chair, and thank you to my colleague and my good friend, Mr. May, for coming.
I don't think you will find anybody who is against your intent. I think it's very admirable, but we're here sitting in the finance committee, so dollars and cents and data drive our decision-making.
I've looked at the numbers. I've heard your testimony. The consideration is about the uptick and the cost-benefit analysis, and it goes both ways.
You said there isn't clear research because something like this hasn't been done anywhere before. Can you elaborate on that a little bit?